Study title:
Kucukoduk, S., Sezer, T., Yildiran, A. and Albayrak, D. Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis Scandinavian Journal of Infectious Diseases 34(12): 893-897.Kucukoduk, S., Sezer, T., Yildiran, A. and Albayrak, D. Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to non-neutropenic preterm newborns between 33 and 36 weeks with presumed sepsis Scandinavian Journal of Infectious Diseases 34(12): 893-897.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Immune System Diseases
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: FILGASTRIM |
ATC code: L03AA02
|
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
Y
|
-
|
-
|
-
|
-
|